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L
ymphocytic inﬁltration in the islets of Langerhans
is generally recognized as the deﬁning lesion in
young patients with recent-onset type 1A diabe-
tes. In a landmark article published in Diabetes in
1965, Gepts (1) described insulitis in 70% of cases with
acute diabetes and found that the lesion only affected
islets with residual -cells in pancreatic organs that had
otherwise lost most of their -cell mass. He concluded that
the disease was probably caused by a protracted -cell–
speciﬁc (auto)immune process, thereby initiating a do-
main of study that has led to many new insights into the
disease process, the identiﬁcation of preclinical markers,
and the deﬁnition of new intervention strategies.
Unfortunately, our knowledge of the early disease pro-
cesses leading to the speciﬁc destruction of -cells is far
from complete. Among other things, it is still unknown
what event triggers the T-cell–mediated inﬂammatory pro-
cess, why the inﬁltrate of predominantly CD8
 T-cells and
macrophages is limited to the islets of Langerhans and
only -cells are destroyed, against which antigen the
inﬂammatory inﬁltrate is directed, and whether this anti-
gen is of an endogenous or exogenous nature (2–5). This
lack of knowledge is, to a considerable extent, caused by
the scarcity of material regarding those recently diagnosed
with type 1 diabetes, of which only several dozen cases
have been described in the literature (6). It is especially
due to the virtual absence of material regarding pre-
diabetic individuals who, although identiﬁable with in-
creasing conﬁdence by a combination of autoantibody
assays and genotyping for HLA-DQ–susceptibility markers
(7), cannot easily be investigated due to the difﬁcult
accessibility and diffuse location of the endocrine pan-
creas. Due to this lack of material, researchers have
increasingly turned to animal models that resemble the
human disease. The spontaneously diabetic NOD mouse
has become the object of choice because its diabetes
shares several characteristics with human type 1 diabetes,
although important differences remain with regard to inci-
dence, sex bias, immune processes, and histopathology (8).
In this issue of Diabetes, an exciting study (9) deals with
the question of how circulating immune cells are targeted
to the islets of Langerhans. It is generally thought that in
an inﬂammatory response, leukocytes are primed in drain-
ing lymph nodes and then home to the tissue where the
primary antigen originated. The homing process involves
several different phases of interaction with the vasculature
of the target tissue; these phases involve rolling, ﬁrm
adhesion, and transmigration across the endothelial cell
layer (Fig. 1). All of these steps are closely regulated by
several families of proteins, including the integrins (a
family of 24 heterodimeric transmembrane proteins com-
posed of one -chain and one -chain), that are involved in
intercellular and cell-matrix interactions and are of special
importance in T-cell activation and homing (10). The study
deals with a subclass of four integrins that are composed
of an Itgb2 -chain and one of four possible -chains (-L,
M-, X-, or D-chain). The authors used NOD mouse
strains knocked out for either Itgb2, thus removing leuko-
cyte expression of all four integrins that contain this
subunit, or for the L-chain, thus removing leukocyte
expression of the heterodimer Itgb2/L (also called LFA-
1). Glawe et al. found that both knockouts resulted in the
prevention of diabetes and insulitis, indicating that the 2
class of integrins and, especially, LFA-1 are essential for
the development of the disease in the NOD mouse. More-
over, using an islet endothelial cell adhesion assay and
adoptive transfer experiments, Glawe et al. showed that
this prevention was apparently due to two different mech-
anisms: the Itgb2 knockout interfered with T-cell adhe-
sion, whereas the L-chain knockout interfered with T-cell
activation. These ﬁndings are important, as they may open
new possibilities for treatment in the early stages of the
autoimmune process in autoantibody-positive subjects
who are at high risk for developing the disease or in
recent-onset subjects who still retain a signiﬁcant part of
their -cell mass. These ﬁndings are also important in view
of an existing antibody-based therapy directed against the
intregrin L-chain, thus providing us with a potential new
treatment that could reduce T-cell activation and adhesion
and could signiﬁcantly impair the progress of insulitis.
Clearly, many questions need to be addressed before a
clinical intervention can be considered in diabetic sub-
jects. One question is whether the observations in NOD
mice also pertain to the human disease. This is not a trivial
point, as signiﬁcant differences have been described be-
tween the process of insulitis in the NOD mouse and that
in diabetic patients. In the NOD mouse, there is a pro-
longed phase of relatively benign peri-insulitis followed by
massive aggressive intra-insulitis around week 17 (11).
This two-step process has not been recognized in patients
in whom the insulitis is generally of a much milder nature.
There are also a number of anatomical differences be-
tween mouse and human islets that may affect leukocytic
inﬁltration. The basement membrane in rodents is single
layered, in contrast to human islets where it consists of a
double-layered structure, which has been compared with
the basement membrane of the blood-brain barrier and
may provide a stop signal to lymphocytes (12). On the
other hand, there are also signiﬁcant parallels between
NOD and human insulitis; among these is the overexpres-
sion of the LFA-1 ligand intracellular adhesion molecule-1
(ICAM1) in inﬂamed human islets (13,14), suggesting that
the LFA-1–ICAM-1 pathway is indeed operative in human
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with regard to previous studies in the NOD mouse model
that stressed the importance of other integrins, notably the
4-1 and 4-7 heterodimers (15–17). It will be important
to investigate whether a knockout of the 4-chain will
prevent the disease and whether the 2 integrins indeed
dominate over the other classes of molecules. Glawe et al.
suggest that in light of their results in the NOD mouse, the
clinically available anti–LFA-1 antibody efalizumab could
be useful for the treatment of type 1 diabetes in human
subjects. Although this is indeed an exciting possibility,
there is also need for caution, not only for the reasons
stated above, but also because the drug’s current use for
the treatment of psoriasis is open to debate following
reports of serious adverse effects (18,19).
In summary, the study by Glawe et al. provides impor-
tant new information about the mechanisms of T-cell
activation and homing in the NOD mouse. If the data are
validated in human subjects, these studies may open the
way for new forms of immune intervention that may
complement the currently available therapies.
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FIG. 1. Extravasation of leukocytes involves subsequent stages of tethering and rolling over the (peri-)islet endothelium, followed by ﬁrm
adhesion and transmigration. A plethora of tissue-speciﬁc adhesion molecules is involved that trigger, mediate, or modify leukocyte binding and
migration.
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